Saccharomyces boulardii

Saccharomyces boulardii is not a bacterium — it is a yeast. That distinction matters more than most supplement labels suggest. Because antibiotics kill bacteria but spare yeasts, S. boulardii is one of the few probiotics you can take concurrently with antibiotics without the drug wiping it out. This unique property, combined with a robust clinical trial record, makes it arguably the most evidence-backed single probiotic organism for specific gastrointestinal indications.

The mechanism is multifaceted. S. boulardii secretes a 54-kDa protease that directly neutralizes C. difficile toxins A and B — the same toxins responsible for the severe colitis seen in C. difficile infection. It also produces polyamines that accelerate intestinal mucosal repair, stimulates secretory IgA (the gut’s first antibody line of defense), and modulates inflammatory cytokine profiles toward anti-inflammatory IL-10 and TGF-β. Unlike many bacterial probiotics that simply compete for adhesion sites, S. boulardii actively detoxifies pathogens and repairs the intestinal barrier.

The evidence is strongest for antibiotic-associated diarrhea (AAD). A 2010 meta-analysis by McFarland in Anaerobe pooled 21 RCTs and found S. boulardii reduced AAD risk by 52% (relative risk 0.48) with a number needed to treat (NNT) of approximately 10. Szajewska’s 2015 meta-analysis in Aliment Pharmacol Ther confirmed this with 21 trials including 4,780 participants, showing consistent benefit across age groups and antibiotic classes. For C. difficile recurrence specifically, pooled data show a roughly 60% reduction in recurrence rates when S. boulardii is added to standard antibiotic therapy. Traveler’s diarrhea and pediatric acute infectious diarrhea also show modest but real benefits, with S. boulardii reducing diarrhea duration by approximately one day in children.

The honest framing is equally important. S. boulardii is not a panacea for “gut health.” It does not colonize the gut long-term — it passes through within days of stopping supplementation. Its benefits are acute and indication-specific: AAD prevention, C. difficile recurrence reduction, and shortening of infectious diarrhea. Claims about immune enhancement, skin health, or mood are largely extrapolated from mechanism and lack dedicated RCT support.

Safety requires explicit attention. S. boulardii is generally well tolerated, but rare cases of fungemia (yeast bloodstream infection) have been documented, almost exclusively in immunocompromised patients with central venous catheters. The FDA has issued warnings for use in severely immunocompromised individuals. Patients with yeast allergies should avoid it. A controversial finding from one trial in severe acute pancreatitis suggested increased mortality, though this was not replicated and the mechanism remains unclear. For the general population, side effects are mild — occasional bloating, gas, or constipation.

Practical guidance: Start S. boulardii on the first day of antibiotic therapy for AAD prevention, not after symptoms begin. The typical dose is 250–500 mg (5–10 billion CFU) daily, split into two doses. Continue for 1–2 weeks after antibiotics finish. It is room-temperature stable, making it convenient for travel. Take at least 2 hours apart from antifungal medications. If you are immunocompromised, have a central line, or have severe acute pancreatitis, consult a physician before use.